🇩🇰 Top U.S. Investor Injects Millions into Danish Biotech for Global Growth

Top U.S. investor injects millions into Danish biotech for global growth

EvodiaBio has raised EUR 6 million in a new funding round led by the American investment firm RA Capital. Funds will be used to accelerate the company’s growth journey in Europe, the United States, and Canada, with Asia as the next step in its expansion.

The Danish flavor company EvodiaBio has raised EUR 6 million in a new funding round led by the American investment firm RA Capital. Existing investors, including EIFO, continue their support, while new international investors such as Wild Radicals and Francis Family Funds have come aboard.

The funding will be used to strengthen growth in existing markets and to enter the Asian market.

EvodiaBio has developed a groundbreaking technology platform that enables a viable industrial-scale production of volatile aroma molecules far more efficiently and sustainably than traditional methods, with the potential to transform the beer industry and expand into new applications across the beverage and aroma industries.

The company began as a research project and, in just a few years, has moved from the laboratory to industrial production with documented market demand. Having removed the major technological and commercial risks, EvodiaBio now stands at a turning point where global scaling is the next natural step.

“This investment puts us in a position to scale globally. I am proud of our team – within just three and a half years, we have gone from a research project to industrial production with all necessary approvals and a profitable product. That is rarely seen in the biotech industry. This investment enables us to accelerate global growth and realise our ambition of becoming a Danish unicorn in industrial biotech,” says Camilla Kloss Fenneberg, CEO of EvodiaBio.

Since its launch earlier this year, EvodiaBio has achieved global commercial traction with more than 70 commercial brews and over 10 projects with top-40 breweries worldwide. The company has proven the effectiveness and market relevance of its technology, which has the potential to transform beer production and reduce dependence on hops – a raw material threatened by climate change.

“RA Capital’s investment in EvodiaBio at this stage underscores the company’s strong position. It confirms that we have removed the key risks related to technology, production, and commercialisation. We have proven that the technology works, that customers are interested in the product, and that the business model has been profitable from day one. Now we are ready to accelerate growth,” says Jarne Elleholm, Chairman of the Board at EvodiaBio. He adds:

“What EvodiaBio has achieved in record time is highly unusual in our industry. Moving from the laboratory to a complete production platform, global partnerships, and market interest in such a short time demonstrates that Denmark has the potential to become a leading hub for biosolutions. The new capital allows us to accelerate even further and show how far industrial biotech can take Denmark.”

RA Capital sees significant potential in EvodiaBio’s technology, which has solved one of the most complex challenges in the aroma and beverage industries.

“EvodiaBio has developed a technology platform that convincingly solves one of the most complex problems in the aroma and beverage industries: how to efficiently and sustainably produce natural aromas at industrial scale. The team has executed with a speed and quality rarely seen in biotech, and we see enormous global potential,” says Kyle Teamey, Managing Partner at RA Capital. He adds:

“It is exceptional for a biotech company to already have in-house production, validated technology, strong commercial demand, and established distribution partners at this stage. With Symrise and Lallemand as channels, EvodiaBio has a unique opportunity for rapid market access. We look forward to supporting the company as it is scaled internationally and expands the technology into new segments.”

With its latest investment and strong partnerships, EvodiaBio is well positioned to accelerate its growth. The next steps include expansion into new markets such as Asia and applying its sustainable technology across additional industries, including other beverages, wine, and the aroma industry more broadly.

“This investment places us in a strong position to accelerate our growth and expand our technology into new markets, especially in Asia. We have achieved strong commercial validation, but we are still early in our growth journey. Our goal is to become a global leader in industrial biotech, and we see a tremendous opportunity to enter multiple industries with our sustainable and efficient solutions,” says Camilla Kloss Fenneberg.